This study screens human monoclonal antibodies (mAbs) targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The identified CT-P59 mAb potently neutralizes SARS-CoV-2 isolates, including the D614G variant, without antibody-dependent enhancement. Crystal structure analysis reveals a distinct interaction with the RBD compared to other known mAbs. In vivo studies in ferrets, hamsters, and rhesus monkeys demonstrate therapeutic efficacy, reducing viral load and alleviating symptoms. CT-P59 shows promise as a therapeutic candidate for COVID-19.
Publisher
Nature Communications
Published On
Jan 12, 2021
Authors
Cheolmin Kim, Dong-Kyun Ryu, Jihun Lee, Young-Il Kim, Ji-Min Seo, Yeon-Gil Kim, Jae-Hee Jeong, Minsoo Kim, Jong-In Kim, Pankyeom Kim, Jin Soo Bae, Eun Yeong Shim, Min Seob Lee, Man Su Kim, Hanmin Noh, Geun-Soo Park, Jae Sang Park, Dain Son, Yongjin An, Jeong No Lee, Ki-Sung Kwon, Joo-Yeon Lee, Hansaem Lee, Jeong-Sun Yang, Kyung-Chang Kim, Sung Soon Kim, Hye-Min Woo, Jun-Won Kim, Man-Seong Park, Kwang-Min Yu, Se-Mi Kim, Eun-Ha Kim, Su-Jin Park, Seong Tae Jeong, Chi Ho Yu, Youngjoo Song, Se Hun Gu, Hanseul Oh, Bon-Sang Koo, Jung Joo Hong, Choong-Min Ryu, Wan Beom Park, Myoung-don Oh, Young Ki Choi, Soo-Young Lee
Tags
monoclonal antibodies
SARS-CoV-2
therapeutic efficacy
viral load
crystal structure
COVID-19
RBD
Related Publications
Explore these studies to deepen your understanding of the subject.
